Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis

Objective: The last edition of the AJCC staging system eliminated the pT2 subclassification of prostate cancer (PCa). Our objective was to evaluate the association of pT2 subclassification with the oncological results of patients with PCa who underwent radical prostatectomy (RP). Material and methods: We evaluated 367 patients who underwent RP between 2009 and 2016, with pT2 disease in the final pathological evaluation. We assessed differences in rates of biochemical recurrence (BCR), metastasis and mortality between T2 substages (pT2a/b vs pT2c). Results: Fifty-three (14.4%) patients presented pT2a/b disease and 314 (85.6%) pT2c disease. The mean follow-up time was 4.9 ± 2.6 years. Grade group scores (p = 0.1) and prostate specific antigen (PSA) (p = 0.2) did not differed between pT2 substages. The rate of BCR in pT2a/b and pT2c patients was 11.3% and 18.2%, respectively (p = 0.2). Five (9.4%) patients with pT2a/b and 45 (14.3%) with pT2c substage underwent salvage radiotherapy (p = 0.3). The rate of positive surgical margins did not differ between groups (p = 0.2). Seven (2.2%) patients with pT2c had lymph nodes or distant metastases. The overall survival was 92.5% and 93.6% in pT2a/b and pT2c, respectively (p = 0.2). Conclusion: Our results are in accordance with the changes introduced in the 8th edition of the AJCC staging system in which the pT2 subclassification was eliminated.

Download Full-text

Validation of the 8th edition of the UICC/AJCC staging system for nasopharyngeal carcinoma treated with intensity-modulated radiotherapy

Oncotarget ◽

10.18632/oncotarget.19829 ◽

2017 ◽

Vol 8 (41) ◽

pp. 70586-70594 ◽

Cited By ~ 10

Author(s):

Min Kang ◽

Pingting Zhou ◽

Guisheng Li ◽

Haolin Yan ◽

Guosheng Feng ◽

...

Keyword(s):

Nasopharyngeal Carcinoma ◽

Intensity Modulated Radiotherapy ◽

Staging System ◽

Intensity Modulated ◽

Ajcc Staging System ◽

Ajcc Staging ◽

8Th Edition

Download Full-text

The Prognostic Value of the 8th Edition of the American Joint Committee on Cancer (AJCC) Staging System in HER2- Enriched Subtype Breast Cancer, a Retrospective Analysis

Anticancer Research ◽

10.21873/anticanres.11862 ◽

2017 ◽

Vol 37 (8) ◽

Cited By ~ 1

Keyword(s):

Breast Cancer ◽

Retrospective Analysis ◽

Prognostic Value ◽

Staging System ◽

American Joint Committee ◽

Ajcc Staging System ◽

Ajcc Staging ◽

8Th Edition

Download Full-text

A review of the 8th edition of the AJCC staging system for oropharyngeal cancer according to HPV status

European Archives of Oto-Rhino-Laryngology ◽

10.1007/s00405-020-05979-9 ◽

2020 ◽

Vol 277 (9) ◽

pp. 2407-2412 ◽

Cited By ~ 1

Author(s):

Piotr Machczyński ◽

Ewa Majchrzak ◽

Patryk Niewinski ◽

Joanna Marchlewska ◽

Wojciech Golusiński

Keyword(s):

Oropharyngeal Cancer ◽

Staging System ◽

Cancer Staging ◽

Nodal Metastasis ◽

Clinical Staging ◽

Previous Edition ◽

Hpv Status ◽

Ajcc Staging System ◽

Ajcc Staging ◽

8Th Edition

Abstract Background The incidence of oropharyngeal squamous cell carcinoma (OPSCC) has increased substantially in recent decades, particularly p16-positive human papillomavirus (HPV)-related OPSCC, which has risen by 50% in western countries. HPV-positivity is the most favourable non-anatomic predictor of oropharyngeal cancer outcomes, which underscores the importance of incorporating this variable into the cancer staging system. Methods In the present article, we review the differences between the 7th and 8th editions of the AJCC staging system, with particular focus on the role of HPV-positivity in patients with head and neck cancer. Results In the previous edition (7th edition) of the AJCC/UICC manual, HPV status and its correlation with nodal metastasis were not considered, thereby leading to incorrect lymph node (N) staging and, potentially, inadequate treatment and worse outcomes. The 8th edition of the AJCC manual addresses these issues, providing more accurate discrimination between groups and better risk stratification in patients with HPV-positive OPSCC. In the future, additional adjustments are likely to be needed, such as unification of the pathological and clinical staging models. Conclusions The new staging system is substantially more accurate than the previous system and should be widely adopted in routine clinical practice.

Download Full-text